Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Bicycle Therapeutics PLC changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 107 | 1 | 105 | −1 |
| Shares | 39.7M | 402.2K | 40.4M | +1.12M (+2.8%) |
| Value | $804.0M | $8.14M | $915.3M | +$119.4M (+15.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Bicycle Therapeutics PLC at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 500,000 | $11.3M | 1.27% |
| Principal Financial Group Inc | 443,141 | $10.0M | 0.01% |
| BlackRock, Inc. | 419,763 | $9.50M | 0.00% |
| FMR LLC | 150,516 | $3.41M | 0.00% |
| Silvercrest Asset Management Group LLC | 139,093 | $3.15M | 0.02% |
| Granahan Investment Management Inc | 96,916 | $2.19M | 0.09% |
| Altium Capital Management LP | 85,000 | $1.92M | 0.57% |
| Palo Alto Investors LP | 59,582 | $1.35M | 0.18% |
| Davenport & Co LLC | 20,650 | $467.3K | 0.00% |
| NEOS Investment Management LLC | 17,652 | $399.5K | 0.01% |
| Nomura Holdings Inc | 13,095 | $296.3K | 0.00% |
| Crossmark Global Holdings, Inc. | 11,367 | $257.0K | 0.00% |
| Pathstone Holdings, LLC | 10,228 | $231.5K | 0.00% |
| Assetmark, Inc | 1,519 | $34.4K | 0.00% |
| Clear Street Markets LLC | 97 | $2.00K | 0.00% |
| Wells Fargo & Company | 30 | $679 | 0.00% |
| EverSource Wealth Advisors, LLC | 20 | $453 | 0.00% |
Sold out (18)
Institutions that held Bicycle Therapeutics PLC at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Avoro Capital Advisors LLC | 700,000 | $14.2M |
| Woodline Partners LP | 586,622 | $11.9M |
| Pinnacle Associates Ltd | 242,001 | $4.90M |
| Rubric Capital Management LP | 205,423 | $4.16M |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 125,283 | $2.54M |
| Comerica Bank | 110,940 | $2.25M |
| National Bank of Canada | 48,700 | $988.1K |
| Millennium Management LLC | 37,507 | $759.1K |
| Two Sigma Investments, LP | 26,583 | $538.0K |
| Bellevue Group AG | 16,000 | $323.8K |
| Dymon Asia Capital (Singapore) Pte. Ltd. | 15,000 | $303.6K |
| Goldman Sachs Group Inc | 13,907 | $281.5K |
| Natixis Advisors, L.P. | 12,912 | $261.0K |
| Walleye Trading LLC | 10,471 | $211.9K |
| XTX Topco Ltd | 10,177 | $206.0K |
| Aquatic Capital Management LLC | 5,500 | $111.3K |
| Gen-Wealth Partners Inc | 39 | $789 |
| Mather Group, LLC. | 5 | $125 |
Not filed for Q3 2024 yet (1)
Institutions that held Bicycle Therapeutics PLC at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 402,223 | $8.14M |